ATYR aTyr Pharma, Inc. Common Stock
XNAS 0.12 DelayedStock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
ATYR
$0.12
—
Key stats
$0.12
- 52-Week Range
- $0.12 – $1.11
- YTD
- -84.31%
- Straddle Price
- $10.38
- P/C Vol Ratio
- 1.11
- Market Cap
- $0.0B
- Open
- $0.12
- Day Range
- $0.12 – $0.13
- Volume
- 1,658,313
- Prev Close
- $0.15
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 1.20 |
| Cost of Equity (CAPM) | 11.59% (VRP-adj) |
| WACC | 11.61% |
| Volatility Risk Premium | +994.7pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -124.6% |
| Book / Price | 398.0% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | -28852.1% |
| Debt / Equity | 0.00 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $0.36 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $0.23 |
| Bollinger Width / SMA20 | 43177.6% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
Peers used for multiples: AMGN, BIIB, EXEL, GILD, HALO, MRNA, NBIX, RGEN, RVMD, TECH
(SIC-code peers; ETF co-membership was sector-incoherent)
Blended Fair Value
$1.23
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 34.5× · 7 peers |
| Peer EV/EBITDA | n/a | 0% | median 18.3× · 8 peers |
| Peer P/B | $6.25 | 16% | median 10.2× · 10 peers |
| Peer P/S | $0.01 | 16% | median 6.6× · 9 peers |
| Market Anchor (SMA50) | $0.36 | 69% | stability 85% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 58
- List Date
- 2015-05-07
- CIK
- 0001339970
- Next Earnings
- 2026-11-05 (Pre-Market)
- EPS Forecast
- ($0.11) (2 est.)
- Headquarters
- San Diego, CA
- Homepage
- https://www.atyrpharma.com
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '24 | '25 | '26 | Avg |
|---|---|---|---|---|
| Jan | -- | -1.28% | 16.30% | 7.51% |
| Feb | -- | 10.78% | -1.07% | 4.85% |
| Mar | -- | -8.48% | -21.21% | -14.85% |
| Apr | -- | 20.49% | -5.10% | 7.69% |
| May | -- | 33.83% | -34.91% | -0.54% |
| Jun | -14.29% | 6.74% | 9.18% | 0.54% |
| Jul | 26.92% | -7.99% | -19.16% | -0.08% |
| Aug | -4.10% | 14.47% | 8.07% | 6.15% |
| Sep | -1.12% | -87.23% | -36.41% | -41.59% |
| Oct | 81.40% | 25.43% | -60.22%* | 15.54% |
| Nov | 16.12% | -11.38% | -- | 2.37% |
| Dec | 1.69% | 5.67% | -- | 3.68% |
| Total | 120.96% | -72.78% | -86.49% | -12.77% |
* Only 3 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $0.22
SMA 50: $0.35
SMA 200: $0.61
Current: $0.12
EMA 12: $0.18
EMA 26: $0.24
MACD: -0.0593 | Signal: -0.0002
BEARISH
ADX (14): 67.72
STRONG TREND
+DI: 3.70
−DI: 46.13
Momentum Oscillators
RSI (14): 10.28
OVERSOLD
Stoch %K: 4.22
Stoch %D: 4.45
Williams %R: -97.72
Volume & Volatility
BB Upper: $0.33
BB Lower: $0.10
NEUTRAL
OBV: -305,682,493
Vol SMA 20: 1,838,483
Vol ROC: -41.87%
ATR: $0.02
True Range: $0.04
HV 20: 97.8%
HV 30: 93.6%
HV 60: 87.3%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report
SYMBOL: ATYR
Executive Summary Overall Assessment: BEARISH (Confidence Level: 6/10) Key Drivers: Technical indicators, options metrics, recent news headlines Primary Risks: High volatility, negative sentiment from lawsuit and class action alerts, potential earnings miss Investment Thesis: aTyr Pharma's high volatility and bearish momentum suggest caution is warranted. Recent News Sentiment Impact: Negative news headlines dominated the past few weeks, contributing to the bearish tone.
Technical Analysis Trend Direction:
- Short-term (1-4 weeks): Downtrend (SMA 20 $0.52 < current price $0.46)
- Medium-term (1-3 months): Range-bound (ADX 14 16.85 - regime: range)
- Long-term (3-12 months): Uptrend (SMA 200 $0.69 > SMA 50 $0.53)
Support/Resistance Levels:
- Upper Bollinger Band: $0.58
- Lower Bollinger Band: $0.46
Momentum Signals:
- RSI (14) = 38.30 (neutral)
- MACD: bearish
- Bollinger Bands: oversold
Volume Analysis:
- Volume SMA 20: 633685.55
- On-Balance Volume (OBV): -115767700.00
- Volume Rate of Change: 22.37%
News & Sentiment Analysis Recent Headlines Summary: Negative news headlines dominated the past few weeks, highlighting lawsuit and class action alerts. Sentiment Assessment: Negative sentiment from recent news headlines.
Catalyst Identification:
- No imminent catalysts identified
Market Narrative: The negative news headlines have contributed to a bearish tone in the market, aligning with the technical signals.
Risk & Volatility Assessment Beta Interpretation: High risk (beta 1.90 > market beta)
Volatility Regime: High volatility (volatility rank: 18.6%)
Options Market Signals:
- IV Rank: 18.6% (Low)
- Put/Call Volume Ratio: 0.50 (Bullish sentiment)
- Put/Call OI Ratio: 0.12
Downside Protection: Support levels and risk management considerations.
Market Context & Positioning Sector Performance: Weak performance in the biotech sector. Institutional Activity: Moderate institutional interest signals.
Correlation Analysis:
- Correlation with SPY: 0.18 (low)
Relative Valuation:
- Relative strength vs market: Weakest performer among peers.
Key Levels & Action Items Critical Price Levels:
- Lower Bollinger Band: $0.46
- Upper Bollinger Band: $0.58
Breakout/Breakdown Levels:
- SMA 20: $0.52 (resistance)
Time-Sensitive Catalysts:
- No imminent catalysts identified
Risk Management:
- Stop-loss levels and position sizing considerations.
Conclusion The bearish momentum in ATYR's technical indicators, combined with negative news headlines, suggests caution is warranted. The high volatility and beta suggest a high-risk profile. A conservative approach with careful risk management is recommended.
Generated
News
All ATYR news →
Earnings History
6 of 7 under expected move
Avg Expected Move
36.76%
Avg Actual Move
6.08%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2025-03-13 | Pre-Market | 71.83% | 12.39% | 0.17x | Within |
| 2025-05-07 | Pre-Market | 64.24% | 2.17% | 0.03x | Within |
| 2025-08-08 | Pre-Market | 20.04% | 1.15% | 0.06x | Within |
| 2025-11-06 | Pre-Market | 27.65% | 5.35% | 0.19x | Within |
| 2026-03-05 | Pre-Market | 36.29% | 6.45% | 0.18x | Within |
| 2026-05-15 | Pre-Market | 8.93% | 9.98% | 1.12x | Exceeded |
| 2026-08-06 | Pre-Market | 28.36% | 5.10% | 0.18x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
ATYR Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: $10.38
7-DTE Move: $10.38
Days to Exp: 24 (2026-11-20)
Options Flow
Call Volume: 9
Put Volume: 10
P/C Volume: 1.111
NEUTRAL
Call OI: 2,076
Put OI: 39
P/C OI: 0.019
Total OI: 2,115
ATM Options Pricing
ATM Call: $10.00
ATM Put: $0.38
Call %: 8396.3%
Put %: 314.9%
Chain Summary
Chain Volume: 545
Chain OI: 34,672
Last Updated: 10/27/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 23rd percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
23%
vs own history
GEX tilt
+0.79
OI-weighted, today
Vanna tilt
+0.77
δ-sensitivity to IV
Charm tilt
-0.80
δ-decay vs time
Vanna tilt +0.77: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.80: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 4 ATM contracts, 1k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 1002.9% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$10.38Oct 27
Beta Analysis
Risk Metrics
Beta: 2.4609
Alpha: -179.17%
Correlation: 0.2854
R-Squared: 8.1%
Stock Volatility: 109.4%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own ATYR
5 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $741K | #4036 of 6285 | +2521.9% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $392K | #3262 of 3716 | -60.0% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $99K | #2980 of 3138 | +307.7% | 13F | |
| Point72 Hedge fund Steve Cohen | $22K | #1916 of 1945 | new | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $17K | #3798 of 4729 | 0.0% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
ATYR Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 94,575,743 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
8 filers$736.20K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Wolverine Trading, LLC Custodian | $163.10K | 22.15% | 2025-09-30 |
| 2 | Citadel Advisors LLC Custodian | $148.60K | 20.19% | 2026-06-30 |
| 3 | GROUP ONE TRADING LLC Custodian | $125.69K | 17.07% | 2026-06-30 |
| 4 | Jane Street Group, LLC Custodian | $106.59K | 14.48% | 2026-06-30 |
| 5 | Susquehanna International Group, LLP Custodian | $92.88K | 12.62% | 2026-06-30 |
| 6 | Simplex Trading, LLC Custodian | $92.06K | 12.50% | 2026-06-30 |
| 7 | TORONTO DOMINION BANK | $7.28K | 0.99% | 2026-06-30 |
| 8 | HAP TRADING, LLC | $6 | <0.01% | 2025-09-30 |
9 filers$246.92K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Wolverine Trading, LLC Custodian | $110.45K | 44.73% | 2025-09-30 |
| 2 | Susquehanna International Group, LLP Custodian | $69.90K | 28.31% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $34.14K | 13.83% | 2026-06-30 |
| 4 | GROUP ONE TRADING LLC Custodian | $10.32K | 4.18% | 2026-06-30 |
| 5 | Jane Street Group, LLC Custodian | $8.95K | 3.63% | 2026-06-30 |
| 6 | DIADEMA PARTNERS LP | $7.46K | 3.02% | 2026-06-30 |
| 7 | Persistent Asset Partners Ltd | $5.21K | 2.11% | 2026-06-30 |
| 8 | Simplex Trading, LLC Custodian | $477 | 0.19% | 2026-06-30 |
| 9 | FNY Investment Advisers, LLC | $0 | 0.00% | 2026-09-30 |
ATYR Insider Trading (Form 4)
Latest: 2026-10-01Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Brandon Yaras | Chief Financial Officer | Grant (A) | +410,000 opt | — | EDGAR | |
| 2026-05-28 | Paul Schimmel | Director | Buy (P) | +100,000 | $0.50 | $49.6K | EDGAR |
| 2026-05-13 | Jane A Gross | Director | Grant (A) | +50,000 opt | — | EDGAR | |
| 2026-05-13 | Sara Zaknoen | Director | Grant (A) | +50,000 opt | — | EDGAR | |
| 2026-05-13 | Svetlana Lucas | Director | Grant (A) | +50,000 opt | — | EDGAR | |
| 2026-05-13 | Paul Schimmel | Director | Grant (A) | +50,000 opt | — | EDGAR | |
| 2026-05-13 | Timothy Coughlin | Director | Grant (A) | +50,000 opt | — | EDGAR | |
| 2026-05-13 | Eric Benevich | Director | Grant (A) | +50,000 opt | — | EDGAR | |
| 2026-02-04 | Sanjay Shukla | President and CEO | Mixed | +6,630 | $0.98 | -$3.7K | EDGAR |
| 2026-02-04 | Jill Marie Broadfoot | Chief Financial Officer | Mixed | +2,192 | $0.98 | -$1.5K | EDGAR |
| 2026-02-04 | Nancy Denyes | General Counsel | Mixed | +1,569 | $0.98 | -$1.1K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
ATYR Insider Holdings
4 insiders · @ $0.12
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Paul Schimmel | Director | 1,421,913 | $169.2K | $49.6K | 2 | 2026-05-28 |
| 2 | Sanjay Shukla | President and CEO | 153,553 | $18.3K | -$3.7K | 1 | 2026-02-04 |
| 3 | Jill Marie Broadfoot | Chief Financial Officer | 38,854 | $4.6K | -$1.5K | 1 | 2026-02-04 |
| 4 | Nancy Denyes | General Counsel | 33,124 | $3.9K | -$1.1K | 1 | 2026-02-04 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ATYR Board & Officers
As of SEC filings through Oct 1, 2026Directors 7
- Paul Schimmel · since May 6, 2015
- Timothy Coughlin · since Apr 7, 2017
- Jane A Gross · since Jun 28, 2019
- Svetlana Lucas · since Jun 28, 2019
- Sanjay Shukla · listed since Jun 2020
- Sara Zaknoen · since May 21, 2021
- Eric Benevich · since Dec 10, 2024
Officers 3
- Sanjay Shukla · President and CEO · listed since Nov 2017
- Brandon Yaras · Chief Financial Officer · since Oct 1, 2026
- Nancy Denyes · General Counsel · listed since Feb 2019
Changes in the last 10 years (17)
| Oct 1, 2026 | Brandon Yaras became Chief Financial Officer |
| Dec 10, 2024 | Eric Benevich became a director |
| May 21, 2021 | Sara Zaknoen became a director |
| Jun 23, 2020 | Sanjay Shukla first listed as a director in an SEC filing |
| Jun 28, 2019 | Svetlana Lucas became a director |
| Jun 28, 2019 | Jane A Gross became a director |
| Feb 8, 2019 | Nancy Denyes listed as General Counsel (previously VP, Legal Affairs) in SEC filings |
| Jul 30, 2018 | Jill Marie Broadfoot became Chief Financial Officer |
| Jun 7, 2018 | Ashraf Amanullah reported in an SEC filing no longer being Vice President, Manufacturing |
| May 16, 2018 | EcoR1 Capital Fund Qualified, L.P. reported in an SEC filing no longer being a 10% owner |
| Jan 2, 2018 | John Mendlein no longer listed as CEO and Director in SEC filings |
| Nov 3, 2017 | Sanjay Shukla listed as President and CEO (previously Chief Medical Officer) in SEC filings |
| Aug 28, 2017 | EcoR1 Capital Fund Qualified, L.P. became a 10% owner |
| May 11, 2017 | Stan Blackburn no longer listed as Acting Chief Financial Officer in SEC filings |
| Apr 7, 2017 | Timothy Coughlin became a director |
| Apr 3, 2017 | Jeffrey S. Hatfield became a director |
| Feb 9, 2017 | John T Blake listed as Senior Vice President, Finance (previously Vice President, Finance) in SEC filings |
Not reported recently (12)
- Jill Marie Broadfoot · Last reported as Chief Financial Officer in an SEC filing dated Feb 4, 2026
- John K Clarke · Last reported as a director in an SEC filing dated May 23, 2024
- Jeffrey S. Hatfield · Last reported as a director in an SEC filing dated May 8, 2020
- James C Blair · Last reported as a director in an SEC filing dated May 10, 2019
- John Mendlein · Last reported as a director in an SEC filing dated May 10, 2019
- Amir Nashat · Last reported as a director in an SEC filing dated May 17, 2018
- John T Blake · Last reported as Senior Vice President, Finance in an SEC filing dated Feb 8, 2018
- David John King · Last reported as Senior Vice President, Research in an SEC filing dated Feb 8, 2018
- Srinivas Akkaraju · Last reported as a director in an SEC filing dated May 11, 2017
- Mark Alan Goldberg · Last reported as a director in an SEC filing dated May 11, 2017
- Sanuj K. Ravindran · Last reported as Chief Business Officer in an SEC filing dated Feb 9, 2017
- Grove Matsuoka · Last reported as Senior Vice President, Product Programs & Planning in an SEC filing dated Feb 9, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
3 ETFs hold ATYR
3 shown · $1.13M total exposure
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.73
TTM Revenue
$190.00K
TTM Net Income
$-70.03M
TTM Op. Cash Flow
$-59.08M
Quarterly figures (8 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q1 '26 | 2026-03-31 | — | $-10.79M | $-0.11 | $-12.52M |
| Q4 '25 | 2025-12-31 | $0.00 | $-13.96M | $-0.14 | $-12.20M |
| Q3 '25 | 2025-09-30 | $190.00K | $-25.74M | $-0.26 | $-20.48M |
| Q2 '25 | 2025-06-30 | — | $-19.53M | $-0.22 | $-13.89M |
| Q1 '25 | 2025-03-31 | — | $-14.88M | $-0.17 | $-15.42M |
| Q4 '24 | 2024-12-31 | $0.00 | $-14.97M | $-0.17 | $-13.13M |
| Q3 '24 | 2024-09-30 | — | $-17.26M | $-0.23 | $-13.16M |
| Q2 '24 | 2024-06-30 | — | $-16.31M | $-0.23 | $-20.45M |
Q1 2026 • period ending 2026-03-31 • filed 2026-05-15
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
0.19
P/S
58.24
EV/EBITDA
—
EV/Sales
6.36
ROE
-121.3%
ROA
-87.9%
Div Yield
0.00%
FCF Yield
-533.95%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$11.07M
as of 2026-10-27
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
12.89M
SI % of Float
13.19%
Days to Cover
1.00
Short Vol Ratio
56.5%
Free Float
97.76M
Float %
99.7%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-27